Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 12
- Registration Number
- NCT02043847
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 3
- Registration Number
- NCT02043860
- Locations
- 🇺🇸
UIC Cancer Center, Chicago, Illinois, United States
Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia
- Conditions
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2015-12-28
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 2
- Registration Number
- NCT02007863
- Locations
- 🇺🇸
Jackson Memorial Hospital, Miami, Florida, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 240
- Registration Number
- NCT01998971
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2013-11-29
- Last Posted Date
- 2013-11-29
- Lead Sponsor
- Nanjing University School of Medicine
- Target Recruit Count
- 56
- Registration Number
- NCT01998503
- Locations
- 🇨🇳
Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT01983969
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- University of Louisville
- Registration Number
- NCT01969942
- Locations
- 🇺🇸
Pediatric Hematology/Oncology University of Louisville, Louisville, Kentucky, United States
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
- Conditions
- Interventions
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 100
- Registration Number
- NCT01962415
- Locations
- 🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-09-05
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 11
- Registration Number
- NCT01936090
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2013-08-13
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01921387
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.